TD ADSORBED 2 LF / 0.5 ML — DIN 02528401
DIPHTHERIA TOXOID ADSORBED : 2 LF / 0.5 ML TETANUS TOXOID ADSORBED : 5 LF / 0.5 ML · SANOFI PASTEUR LIMITED · SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is TD ADSORBED?
TD ADSORBED 2 LF / 0.5 ML contains DIPHTHERIA TOXOID ADSORBED : 2 LF / 0.5 ML TETANUS TOXOID ADSORBED : 5 LF / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02528401, held by SANOFI PASTEUR LIMITED, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 09-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TD ADSORBED used for?
Active primary and booster immunization for the prevention of tetanus and diphtheria in persons 7 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Tetanus Toxoid, Comb. With Diphtheria Toxoid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Tetanus Toxoid, Comb. With Diphtheria Toxoid, across 5 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI PASTEUR LIMITED | 2 | 1 | TD ADSORBED | Sourceable in Canada |
| AVENTIS PASTEUR LIMITED | 1 | 0 | DIPHTHERIA AND TETANUS TOXOIDS ADSORBED | No marketed DIN |
| ID BIOMEDICAL CORPORATION OF QUEBEC | 1 | 0 | D2T5 | No marketed DIN |
| LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | 1 | 0 | TETANUS AND DIPHTHERIA TOXOIDS ADSORBED FOR ADULT USE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 LF / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | 0.5 mL single dose glass vials (Type 1). Available in packages of 5 (with 2-phenoxyethanol) or 10 (without 2-phenoxyethanol) vials. Latex-free closure. |
| Storage | Store at 2° to 8°C (35° to 46°F). Do not freeze. Discard if exposed to freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Tetanus Toxoid, Comb. With Diphtheria Toxoid |
|---|---|
| ATC code | J07AM51 |
| AHFS class | 80:08.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02528401 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2528401 |
| Brand name | TD ADSORBED |
| Generic / active ingredient | DIPHTHERIA TOXOID ADSORBED : 2 LF / 0.5 ML TETANUS TOXOID ADSORBED : 5 LF / 0.5 ML |
| Market authorization holder | SANOFI PASTEUR LIMITED |
| Health Canada schedule | Schedule D |
| ATC code | J07AM51 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AM |
| Current status | MARKETED |
| Status date | 09-Apr-2024 |
| Original market date | 2024-04-09 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Primary: 3 doses (0.5 mL); first two 4-8 weeks apart, third 6-12 months later. Booster: Single 0.5 mL dose every 10 years. Administer IM, preferably in the deltoid. Shake well before use.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known systemic hypersensitivity to any component or life-threatening reaction after previous administration of the vaccine or a vaccine containing the same components.
Warnings and precautions
Postpone in acute/febrile disease. Risk of brachial neuritis or Guillain-Barré syndrome. Caution in patients with bleeding disorders (IM injection risk). Syncope may occur.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| D2T5 | 5 LF / 0.5 ML | SUSPENSION | ID BIOMEDICAL CORPORATION OF QUEBEC | CANCELLED POST MARKET | 01915274 |
| DIPHTHERIA AND TETANUS TOXOIDS ADSORBED | 5 LF / 0.5 ML | LIQUID | AVENTIS PASTEUR LIMITED | CANCELLED POST MARKET | 00521841 |
| TD ADSORBED | 5 LF / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | 00514462 |
| TETANUS AND DIPHTHERIA TOXOIDS ADSORBED FOR ADULT USE | 5 LF / 0.5 ML | SUSPENSION | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | CANCELLED POST MARKET | 02215098 |
2 · Same class — other molecules in ATC J07AM
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tetanus Toxoid, Comb. With Diphtheria Toxoid | D2T5 · DIPHTHERIA AND TETANUS TOXOIDS ADSORBED · TD ADSORBED · TETANUS AND DIPHTHERIA TOXOIDS ADSORBED FOR ADULT USE | 5 | 1 | Yes |
| Tetanus Toxoid | TETANUS TOXOID ADSORBED · TETANUS TOXOID ADSORBED INJ | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AH | Meningococcal Vaccines · Meningococcus B, Multicomponent Vaccine · Meningococcus C, Purified Polysaccharides Antigen Conjugated · Meningococcus, A, C, Bivalent Purified Polysacc. Antigen · Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen · +1 more | 17 | 6 |
| J07AL | Pneumococcus, Purified Polysacc.antigen Conjugated · Pneumococcus, Purified Polysaccharides Antigen | 11 | 3 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AX | Other Bacterial Vaccines | 4 | 1 |
| J07AG | Hemophilus Influenzae B Vaccines · Hemophilus Influenzae B, Combinations With Pertussis And Toxoids · Hemophilus Influenzae B, Combinations With Toxoids · Hemophilus Influenzae B, Purified Antig. Conjugated | 8 | 1 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AN | Tuberculosis, Live Attenuated | 2 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.